首页 | 本学科首页   官方微博 | 高级检索  
     


A proteomic and phosphoproteomic landscape of KRAS mutant cancers identifies combination therapies
Affiliation:1. State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China;2. University of Chinese Academy of Sciences, Beijing, China;3. School of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing, China;4. Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, China;5. Jiangsu Key Laboratory of Marine Pharmaceutical Compound Screening, College of Pharmacy, Jiangsu Ocean University, Lianyungang, China;6. Department of Bioinformatics and Biostatistics, School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Shanghai, China;7. State Key Laboratory of Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences (Beijing), Beijing Institute of Lifeomics, Beijing, China
Abstract:
><ol class=
  • Download : Download high-res image (203KB)
  • Download : Download full-size image
  • Keywords:proteomics  phosphoproteomics  heterogeneity  cancer  therapy  subtype  DOT1L  SHP2  drug sensitivity
    本文献已被 ScienceDirect 等数据库收录!
    设为首页 | 免责声明 | 关于勤云 | 加入收藏

    Copyright©北京勤云科技发展有限公司  京ICP备09084417号